AstraZeneca Enhertu Secures US FDA Approval for HER2-Low Breast Cancer

The US Food and Drug Administration (FDA) has approved Enhertu of AstraZeneca and Daiichi Sankyo for the treatment of adult patients with metastatic HER2-low breast cancer, who have received a prior chemotherapy in the metastatic setting during six months of completing adjuvant chemotherapy. Enhertu is a specifically designed HER2-directed antibody drug conjugate (ADC), that has […]

Continue Reading

Lupin Pharmaceuticals Gets US FDA Nod for Its Renvela Generic Medicine

The pharmaceutical company ‘Lupin’ said that, it has successfully received the approval from the Food and Drug Administration (FDA) of the United States for the company’s ANDA (abbreviated new drug application) Sevelamer Carbonate for the oral suspension. This drug or medicine has been a generic equivalent of the Renvela for the oral suspension produced by […]

Continue Reading